According to the company, the Covid-19 prophylaxis drug is effective in reducing the risk of Covid-19 infections six months after being given, and that it could be used as an effective means of preventing severe disease in individuals who don't have a robust immune response to Covid-19.
A robust immune response can be developed after receiving Covid-19 vaccines.
The images are from the same company.
The therapy called AZD7442 was effective in reducing the risk of death or severe Covid-19 infections when given to patients within three days of symptom onset.
A follow-up of the phase three trials showed that the drug eliminated the risk of death and severe Covid-19 in recipients after six months.
The trials used a 300-milligram dose of AZD7442 into the muscle of people who had not been exposed to Covid-19.
The cocktail could be used to protect people who don't develop a robust immune response after receiving Covid-19 vaccines.
Mene Pangalos, the chief of research and development at AstraZeneca, said that AZD7442 is the only long-acting antibody with Phase III data to demonstrate benefit in both pre-exposure prophylaxis and treatment of Covid-19 with one dose.
The number is big.
700,000. If the FDA grants emergency use authorization for the drug, the total number of doses will be supplied to the U.S. government. In October, the company applied for emergency approval from the FDA.
A previous post-exposure trial suggested that AZD7442 failed to prevent symptoms, but the data from the new trial is encouraging. The June trial showed that the cocktail was only effective in people who had been exposed to the virus. Injection may help reduce the severity of the disease in people who are already exposed. Despite encouraging numbers, the drug will likely have to show a higher level of effectiveness than the other drugs which have shown the ability to reduce the risk of deaths and severe disease in high-risk individuals. Antiviral pills are cheaper and easier to produce than antibody treatments. The pills can be given to patients outside of hospitals, making them an effective tool in places with limited healthcare infrastructure.
The risk of death or developing severe covid is reduced by the Injectable Antibody Cocktail.
Emergency use authorization is sought for Covid Prophylaxis Drug.
Coverage and live updates on the coronaviruses.
